{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:54Z","timestamp":1789584894818,"version":"build-2803163510"},"reference-count":137,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":104,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>Neuroendocrine tumors (NETs) are rare, heterogeneous neoplasms with varying prognoses and management approaches. Peptide receptor radionuclide therapy (PRRT), targeting tumors expressing somatostatin receptors, delivers cytotoxic radiation to tumor cells. While PRRT has demonstrated efficacy in advanced, well-differentiated NETs, the optimal sequencing with other therapies remains an area of active research. This review explores PRRT\u2019s role in NET management, focusing on its mechanisms, clinical efficacy, safety profile, and integration into a multi-modal treatment strategy. We also examine evidence on the sequencing of PRRT with surgery, liver-directed therapy, chemotherapy, and targeted therapies to optimize treatment outcomes. We conducted a comprehensive review of recent clinical trials, cohort studies, and expert consensus guidelines to assess PRRT\u2019s place in the treatment paradigm. Factors influencing treatment sequencing, such as tumor type, receptor expression, disease burden, and patient-specific characteristics, are also discussed. PRRT has proven effective for patients with advanced, somatostatin receptor-positive NETs, especially for inoperable tumors or those progressing after other therapies. While PRRT plays a vital role in management, its sequencing with other treatments remains complex, with evidence supporting its use both early and late in treatment based on individual patient factors. Optimizing its sequencing with other treatments requires further research but offers potential for improved outcomes. A personalized, multidisciplinary approach is essential for maximizing PRRT\u2019s benefits in NET management. This review article summarizes current evidence and describes patient-specific circumstances, enabling treatment provider to make informed PRRT sequencing decisions.<\/jats:p>","DOI":"10.1530\/erc-25-0495","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:42:34Z","timestamp":1772458954000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":1,"title":["PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)"],"prefix":"10.1530","volume":"33","author":[{"given":"Virginia","family":"Corbett","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Gupta","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0136-1983","authenticated-orcid":true,"given":"Aman","family":"Chauhan","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"2026070909452807500_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2026070909452807500_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026070909452807500_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaoncol.2019.4568","article-title":"Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in incidence","volume":"6","author":"Chauhan","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026070909452807500_bib4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"2026070909452807500_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000080742","article-title":"Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment","volume":"80","author":"Reubi","year":"2004","journal-title":"Neuroendocrinology"},{"key":"2026070909452807500_bib6","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/ijms23031447","article-title":"Role of somatostatin signalling in neuroendocrine tumours","volume":"23","author":"Rogoza","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026070909452807500_bib7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1159\/000513249","article-title":"Unique metastatic patterns in neuroendocrine neoplasms of different primary origin","volume":"111","author":"Hermans","year":"2021","journal-title":"Neuroendocrinology"},{"key":"2026070909452807500_bib8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/OP.23.00445","article-title":"Systemic therapy for tumor control in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors: ASCO guideline Q and A","volume":"19","author":"Del Rivero","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2026070909452807500_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070909452807500_bib10","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026070909452807500_bib11","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026070909452807500_bib12","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I\u2013II study","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070909452807500_bib13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide receptor radionuclide therapy with 177Lu-Octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years\u2019 assessment","volume":"42","author":"Hamiditabar","year":"2017","journal-title":"Clin Nucl Med"},{"key":"2026070909452807500_bib14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours","volume":"41","author":"Ezziddin","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib15","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/imj.14336","article-title":"Safety and outcomes of 177 Lu-DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia","volume":"49","author":"Lin","year":"2019","journal-title":"Intern Med J"},{"key":"2026070909452807500_bib16","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-015-3041-6","article-title":"Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine","volume":"42","author":"Sabet","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib17","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00432-020-03181-2","article-title":"The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis","volume":"146","author":"Zhang","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026070909452807500_bib18","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00259-018-3967-6","article-title":"PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy","volume":"45","author":"Bodei","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00259-019-04601-3","article-title":"PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest","volume":"47","author":"Bodei","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.122.264363","article-title":"Interim analysis of a prospective validation of 2 blood-based genomic assessments (PPQ and NETest) to determine the clinical efficacy of 177Lu-DOTATATE in neuroendocrine tumors","volume":"64","author":"Bodei","year":"2023","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib21","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"2026070909452807500_bib22","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070909452807500_bib23","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"52","author":"Khan","year":"2011","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib24","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909452807500_bib25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2967\/jnumed.110.075226","article-title":"Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors","volume":"51","author":"Menda","year":"2010","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib26","doi-asserted-by":"crossref","first-page":"e3665","DOI":"10.1210\/clinem\/dgab289","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome","volume":"106","author":"Zandee","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909452807500_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","article-title":"Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate","volume":"35","author":"de Keizer","year":"2008","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib28","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites","volume":"34","author":"Sadowski","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026070909452807500_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.diii.2013.07.006","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?","volume":"95","author":"\u00d6ks\u00fcz","year":"2014","journal-title":"Diagn Interv Imaging"},{"key":"2026070909452807500_bib30","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2967\/jnumed.115.162719","article-title":"Prognostic value of 68Ga-DOTANOC PET\/CT SUVmax in patients with neuroendocrine tumors of the pancreas","volume":"56","author":"Ambrosini","year":"2015","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2967\/jnumed.115.166017","article-title":"The impact of 68Ga-DOTATATE PET\/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom","volume":"57","author":"Skoura","year":"2016","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2967\/jnumed.118.215848","article-title":"Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients","volume":"60","author":"Zhang","year":"2019","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2967\/jnumed.120.244798","article-title":"18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study","volume":"62","author":"Binderup","year":"2021","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"key":"2026070909452807500_bib35","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1530\/ERC-18-0424","article-title":"Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study","volume":"26","author":"Carlsen","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026070909452807500_bib37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/ERC-16-0524","article-title":"Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate","volume":"24","author":"Brabander","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2026070909452807500_bib38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.118.230607","article-title":"NANETS\/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib39","article-title":"Therapy sequencing in patients with advanced neuroendocrine neoplasms","volume":"43","author":"Riechelmann","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026070909452807500_bib40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"2026070909452807500_bib41","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026070909452807500_bib42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.6004\/jnccn.2021.7017","article-title":"Efficacy and toxicity analysis of capecitabine and temozolomide in neuroendocrine neoplasms","volume":"20","author":"Al-Toubah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070909452807500_bib43","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070909452807500_bib44","first-page":"247","article-title":"Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs","volume":"5","author":"Peixoto","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"2026070909452807500_bib45","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/curroncol29020046","article-title":"Efficacy of capecitabine and temozolomide in small bowel (midgut) neuroendocrine tumors","volume":"29","author":"Al-Toubah","year":"2022","journal-title":"Curr Oncol"},{"key":"2026070909452807500_bib46","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1530\/ERC-13-0254","article-title":"Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate","volume":"20","author":"Kamp","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"2026070909452807500_bib47","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000506746","article-title":"177Lu-DOTATATE therapy of advanced pancreatic neuroendocrine tumors heavily pretreated with chemotherapy: analysis of outcome, safety, and their determinants","volume":"111","author":"Fr\u00f6ss-Baron","year":"2021","journal-title":"Neuroendocrinology"},{"key":"2026070909452807500_bib48","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00259-007-0457-7","article-title":"Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney","volume":"34","author":"Rolleman","year":"2007","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib49","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00259-005-1793-0","article-title":"Localisation and mechanism of renal retention of radiolabelled somatostatin analogues","volume":"32","author":"Melis","year":"2005","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib50","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026070909452807500_bib51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002590050216","article-title":"Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations","volume":"25","author":"Behr","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"2026070909452807500_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib53","doi-asserted-by":"crossref","first-page":"451","DOI":"10.7150\/thno.92487","article-title":"Long-term nephrotoxicity after PRRT: myth or reality","volume":"14","author":"Baum","year":"2024","journal-title":"Theranostics"},{"key":"2026070909452807500_bib54","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-015-3001-1","article-title":"Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment","volume":"42","author":"Svensson","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib55","first-page":"4102","article-title":"Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs high dose octreotide in progressive midgut neuroendocrine tumors","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Orthod"},{"key":"2026070909452807500_bib56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/bjs.10333","article-title":"Clinical signs of fibrosis in small intestinal neuroendocrine tumours","volume":"104","author":"Daskalakis","year":"2017","journal-title":"Br J Surg"},{"key":"2026070909452807500_bib57","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy","volume":"61","author":"Hope","year":"2020","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib58","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.3390\/cancers14235792","article-title":"A clinical guide to peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients","volume":"14","author":"Becx","year":"2022","journal-title":"Cancers"},{"key":"2026070909452807500_bib59","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2967\/jnumed.121.263056","article-title":"Safety of peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients with chronic kidney disease","volume":"63","author":"Alsadik","year":"2022","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/23993693211050410","article-title":"177 Lu-dotatate use in chronic kidney disease patients: a single center experience","volume":"5","author":"Manohar","year":"2021","journal-title":"J Onco Nephrology"},{"key":"2026070909452807500_bib61","volume-title":"Full Prescribing Information LUTATHERA","author":"Novartis","year":"2021"},{"key":"2026070909452807500_bib62","article-title":"Challenges in von Hippel-Lindau\u2019s disease: PRRT in patients on hemodialysis","volume":"2022","author":"Ayub","year":"2022","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2026070909452807500_bib63","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1097\/RLU.0000000000003202","article-title":"Successful and safe treatment with 177Lu-DOTATATE (Lutathera) of progressive metastatic pancreatic neuroendocrine tumor under hemodialysis","volume":"45","author":"Dierickx","year":"2020","journal-title":"Clin Nucl Med"},{"key":"2026070909452807500_bib64","article-title":"177 Lu-Dotatate therapy for the treatment of metastatic neuroendocrine tumours in a patient on haemodialysis \u2013 dosimetric considerations","volume":"1","author":"Kalogianni","year":"2015","journal-title":"BJR Case Rep"},{"key":"2026070909452807500_bib65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00268-020-05689-7","article-title":"Surgical management of primary small bowel NET presenting acutely with obstruction or perforation","volume":"45","author":"Rajaretnam","year":"2021","journal-title":"World J Surg"},{"key":"2026070909452807500_bib66","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jviscsurg.2020.08.012","article-title":"Radiation enteritis: diagnostic and therapeutic issues","volume":"157","author":"Loge","year":"2020","journal-title":"J Visc Surg"},{"key":"2026070909452807500_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.242875","article-title":"Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy","volume":"62","author":"Strosberg","year":"2021","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib68","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2967\/jnumed.121.262048","article-title":"Bowel obstruction as a complication of peptide receptor radionuclide therapy","volume":"62","author":"Wee","year":"2021","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2011-1264","article-title":"Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing\u2019s syndrome due to ectopic adrenocorticotropin secretion","volume":"97","author":"de Bruin","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909452807500_bib70","first-page":"4112","article-title":"Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors","volume":"39","author":"Strosberg","year":"2021","journal-title":"J Clin Orthod"},{"key":"2026070909452807500_bib71","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1007\/s00259-019-04389-2","article-title":"Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide\/chemoradionuclide therapy (PRRT\/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series","volume":"46","author":"Goncalves","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib72","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib73","doi-asserted-by":"crossref","first-page":"L17","DOI":"10.1530\/ERC-15-0543","article-title":"High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy","volume":"23","author":"Brieau","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2026070909452807500_bib74","first-page":"513","article-title":"Risk of myelodysplastic syndrome\/acute leukemia with sequential capecitabine\/temozolomide and177 Lu-dotatate","volume":"40","author":"Al-Toubah","year":"2022","journal-title":"J Clin Orthod"},{"key":"2026070909452807500_bib75","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1007\/s00277-024-05803-y","article-title":"The role of clonal progression leading to the development of therapy-related myeloid neoplasms","volume":"103","author":"Guarnera","year":"2024","journal-title":"Ann Hematol"},{"key":"2026070909452807500_bib76","article-title":"Mutant PPM1D- and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy","volume":"6","author":"Singh","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026070909452807500_bib77","article-title":"Clonal hematopoiesis in patients with neuroendocrine tumor treated with lutetium-177 and the risk of thrombocytopenia: a prospective study","volume":"8","author":"Kusne","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026070909452807500_bib78","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1111\/cas.15094","article-title":"Clonal hematopoiesis and associated diseases: a review of recent findings","volume":"112","author":"Asada","year":"2021","journal-title":"Cancer Sci"},{"key":"2026070909452807500_bib79","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/PO.20.00046","article-title":"Clonal hematopoiesis in late-stage non-small-cell lung cancer and its impact on targeted panel next-generation sequencing","volume":"4","author":"Yaung","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2026070909452807500_bib80","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4046\/trd.2023.0165","article-title":"Clonal hematopoiesis of indeterminate potential is associated with current smoking status and history of exacerbation in patients with COPD","volume":"87","author":"Lee","year":"2024","journal-title":"Tuberc Respir Dis"},{"key":"2026070909452807500_bib81","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.2337\/dc23-0805","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP) and incident type 2 diabetes risk","volume":"46","author":"Tobias","year":"2023","journal-title":"Diabetes Care"},{"key":"2026070909452807500_bib82","article-title":"Clonal hematopoiesis of indeterminate potential contributes to accelerated chronic kidney disease progression","author":"Vlasschaert","year":"2024","journal-title":"medRxiv"},{"key":"2026070909452807500_bib83","doi-asserted-by":"crossref","first-page":"a006251","DOI":"10.1101\/mcs.a006251","article-title":"Defining clonal hematopoiesis of indeterminate potential: evolutionary dynamics and detection under aging and inflammation","volume":"9","author":"Goldman","year":"2023","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"2026070909452807500_bib84","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12885-021-07961-y","article-title":"The emerging clinical relevance of genomic profiling in neuroendocrine tumours","volume":"21","author":"Burak","year":"2021","journal-title":"BMC Cancer"},{"key":"2026070909452807500_bib85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.beha.2019.02.006","article-title":"Clonal hematopoiesis and therapy related MDS\/AML","volume":"32","author":"Desai","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"2026070909452807500_bib86","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-017-0567-8","article-title":"Radionuclide therapy for neuroendocrine tumors","volume":"19","author":"Cives","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"2026070909452807500_bib87","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"54","author":"Sabet","year":"2013","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib88","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/RLU.0000000000004130","article-title":"Severe thrombocytopenia in patients with advanced neuroendocrine tumor treated with peptide receptor radioligand therapy","volume":"47","author":"Naveed Ahmad","year":"2022","journal-title":"Clin Nucl Med"},{"key":"2026070909452807500_bib89","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bjs.6468","article-title":"Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease","volume":"96","author":"Frilling","year":"2009","journal-title":"Br J Surg"},{"key":"2026070909452807500_bib90","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2967\/jnumed.122.264533","article-title":"Evaluation of hepatotoxicity from peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors and a very high liver tumor burden","volume":"64","author":"Gococo-Benore","year":"2023","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib91","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","author":"van der Zwan","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070909452807500_bib92","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210896","article-title":"The efficacy, toxicity and survival of salvage retreatment PRRT with 177Lu-DOTATATE in patients with progressive NET following initial course of PRRT","volume":"95","author":"Sitani","year":"2022","journal-title":"Br J Radiol"},{"key":"2026070909452807500_bib93","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1186\/s12885-019-6000-y","article-title":"Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival","volume":"19","author":"Rudisile","year":"2019","journal-title":"BMC Cancer"},{"key":"2026070909452807500_bib94","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MNM.0000000000001350","article-title":"Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis","volume":"42","author":"Kim","year":"2021","journal-title":"Nucl Med Commun"},{"key":"2026070909452807500_bib95","volume-title":"Abstract: NET RETREAT: A Phase II Study of 177Lutetium-Dotatate Retreatment vs Everolimus in Metastatic\/Unresectable Midgut NET. EJEA","author":"Aman Chauhan","year":"2023"},{"key":"2026070909452807500_bib96","article-title":"Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro-entero-pancreatic neuroendocrine neoplasms: a scoping review","volume":"37","author":"Kashyap","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"2026070909452807500_bib97","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.2967\/jnumed.120.258772","article-title":"Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors","volume":"62","author":"Parghane","year":"2021","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib98","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2967\/jnumed.115.158899","article-title":"Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3]octreotate","volume":"56","author":"van Vliet","year":"2015","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.687925","article-title":"Value of peptide receptor radionuclide therapy as neoadjuvant treatment in the management of primary inoperable neuroendocrine tumors","volume":"11","author":"Opali\u0144ska","year":"2021","journal-title":"Front Oncol"},{"key":"2026070909452807500_bib100","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.surg.2017.11.007","article-title":"Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms","volume":"163","author":"Partelli","year":"2018","journal-title":"Surgery"},{"key":"2026070909452807500_bib101","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znae178","article-title":"Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study","volume":"111","author":"Partelli","year":"2024","journal-title":"Br J Surg"},{"key":"2026070909452807500_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2024.06.065","article-title":"Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors","volume":"177","author":"Tobias","year":"2025","journal-title":"Surgery"},{"key":"2026070909452807500_bib103","volume-title":"NCCN Clinical Practice Guidelines in Oncology","author":"Network","year":"2024"},{"key":"2026070909452807500_bib104","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jvir.2018.02.002","article-title":"Long-term toxicity after transarterial radioembolization with Yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases","volume":"29","author":"Tomozawa","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"2026070909452807500_bib105","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jvir.2019.06.003","article-title":"Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis","volume":"30","author":"Currie","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"2026070909452807500_bib106","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.jvir.2017.05.011","article-title":"Long-term hepatotoxicity of Yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver","volume":"28","author":"Su","year":"2017","journal-title":"J Vasc Interv Radiol"},{"key":"2026070909452807500_bib107","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.jvir.2020.05.019","article-title":"Chronic hepatotoxicity in patients with metastatic neuroendocrine tumor: transarterial chemoembolization versus transarterial radioembolization","volume":"31","author":"Currie","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"2026070909452807500_bib108","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/RLU.0000000000000935","article-title":"Peptide receptor radionuclide therapy-induced hepatotoxicity in patients with metastatic neuroendocrine tumors","volume":"40","author":"Riff","year":"2015","journal-title":"Clin Nucl Med"},{"key":"2026070909452807500_bib109","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2026070909452807500_bib110","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1159\/000503901","article-title":"Elderly patients with metastatic neuroendocrine tumors are undertreated and have shorter survival: the LyREMeNET study","volume":"110","author":"Lemelin","year":"2020","journal-title":"Neuroendocrinology"},{"key":"2026070909452807500_bib111","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1530\/EC-18-0478","article-title":"Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age","volume":"7","author":"Bongiovanni","year":"2018","journal-title":"Endocr Connections"},{"key":"2026070909452807500_bib112","volume":"90","author":"Capdevila","year":"2023","journal-title":"Endocrine Abstracts"},{"key":"2026070909452807500_bib113","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/ph14101005","article-title":"Combination therapies with PRRT","volume":"14","author":"Yordanova","year":"2021","journal-title":"Pharmaceuticals"},{"key":"2026070909452807500_bib114","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00259-014-2788-5","article-title":"Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)","volume":"41","author":"Kong","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib115","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1007\/s00259-021-05236-z","article-title":"Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors","volume":"48","author":"Nicolini","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070909452807500_bib116","first-page":"561","article-title":"Phase I\u2013II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors","volume":"27","author":"Claringbold","year":"2012","journal-title":"Cancer Biother Radiopharm"},{"key":"2026070909452807500_bib117","first-page":"261","article-title":"Neuroendocrine tumor therapy with Lutetium-177-octreotate and everolimus (NETTLE): a phase I study","volume":"30","author":"Claringbold","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"2026070909452807500_bib118","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.7150\/thno.15311","article-title":"Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib","volume":"6","author":"Nonnekens","year":"2016","journal-title":"Theranostics"},{"key":"2026070909452807500_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67199-9","article-title":"Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP","volume":"10","author":"Cullinane","year":"2020","journal-title":"Sci Rep"},{"key":"2026070909452807500_bib120","article-title":"A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors","volume":"42","author":"Chauhan","year":"2024","journal-title":"J Clin Orthod"},{"key":"2026070909452807500_bib121","volume-title":"Multi-Center NCI-Sponsored Phase 1 Study of Triapine in Combination with 177Lu-Dotatate in Patients With Progressive Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","author":"Aman Chauhan","year":"2025"},{"key":"2026070909452807500_bib122","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2967\/jnumed.123.265391","article-title":"Addition of peptide receptor radiotherapy to immune checkpoint inhibition therapy improves outcomes in neuroendocrine tumors","volume":"64","author":"Esfahani","year":"2023","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib123","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2967\/jnumed.121.262344","article-title":"Response to combined peptide receptor radionuclide therapy and checkpoint immunotherapy with ipilimumab plus nivolumab in metastatic merkel cell carcinoma","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib124","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3390\/pharmaceutics14071466","article-title":"Short-interval, low-dose peptide receptor radionuclide therapy in combination with PD-1 checkpoint immunotherapy induces remission in immunocompromised patients with metastatic merkel cell carcinoma","volume":"14","author":"Aicher","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026070909452807500_bib125","article-title":"A pilot study of pembrolizumab and peptide receptor radionuclide therapy for patients with metastatic well-differentiated neuroendocrine tumors","volume":"98","author":"Fidelman","year":"2023","journal-title":"Endocrine Abstracts"},{"key":"2026070909452807500_bib126","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semradonc.2013.05.009","article-title":"Radiation as an immune modulator","volume":"23","author":"Burnette","year":"2013","journal-title":"Semin Radiat Oncol"},{"key":"2026070909452807500_bib127","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.116.186338","article-title":"\u03b1-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1","volume":"59","author":"Poty","year":"2018","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1034315","article-title":"Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists","volume":"9","author":"Shi","year":"2022","journal-title":"Front Med"},{"key":"2026070909452807500_bib129","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1535-7163.MCT-18-1103","article-title":"Preclinical investigation of 212Pb-DOTAMTATE for peptide receptor radionuclide therapy in a neuroendocrine tumor model","volume":"18","author":"Stallons","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2026070909452807500_bib130","first-page":"4117","article-title":"Phase I dose-escalation study of alphamedix for targeted-alpha-emitter therapy of PRRT-naive neuroendocrine patients","volume":"39","author":"Delpassand","year":"2021","journal-title":"J Clin Orthod"},{"key":"2026070909452807500_bib131","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted \u03b1-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib132","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1158\/1078-0432.CCR-07-4647","article-title":"Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors","volume":"14","author":"Miederer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026070909452807500_bib133","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1158\/1535-7163.MCT-23-0029","article-title":"RYZ101 (Ac-225 DOTATATE) opportunity beyond gastroenteropancreatic neuroendocrine tumors: preclinical efficacy in small-cell lung cancer","volume":"22","author":"Han","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026070909452807500_bib134","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2967\/jnumed.122.264043","article-title":"Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted alpha therapy and capecitabine: a real-world scenario management based long-term outcome study","volume":"64","author":"Ballal","year":"2023","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2967\/jnumed.122.264805","article-title":"The future of targeted \u03b1-therapy is bright, but rigorous studies are necessary to advance the field","volume":"64","author":"Strosberg","year":"2023","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib136","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.2967\/jnumed.116.186502","article-title":"Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of eric P. Krenning by rachel levine","volume":"58","author":"Levine","year":"2017","journal-title":"J Nucl Med"},{"key":"2026070909452807500_bib137","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1078-0432.CCR-05-1264","article-title":"213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model","volume":"12","author":"Norenberg","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/3\/ERC-25-0495.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/3\/ERC-25-0495.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0495\/503025\/erc-25-0495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0495\/503025\/erc-25-0495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:45:47Z","timestamp":1783604747000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/3\/e250495\/75556\/PRRT-for-well-differentiated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0495","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"article-number":"e250495"}}